Le Lézard
Classified in: Health
Subject: PER

VUE HEALTH ANNOUNCES ZARA BAKER AS CHIEF DIGITAL INNOVATION OFFICER


BOSTON, Mass., May 9, 2024 /PRNewswire/ -- VUE Health, a Boston-based healthcare advertising agency, has hired Zara Baker as Chief Digital Innovation Officer. Zara is an MIT-trained innovator and a former scientist with over two decades of healthcare and life science industry experience that spans the US and EU markets within agency and corporate environments. Her expertise includes digital and AI transformation, commercial strategy, launch planning, creative innovation, leadership development and data analytics. Zara will drive digital transformation across VUE Health and the agency's client portfolio and will be launching VUE Lab, a generative AI hub where the industry's brightest minds in science, arts, and engineering will come together to build cutting-edge creative products.

Before joining VUE Health, Zara advised several pre-commercial biotechnology startups and healthcare consulting agencies in a fractional Chief Digital Officer (CDO) capacity. Before that, she was the head of omnichannel strategy at Ionis Pharma and held senior digital roles at various healthcare and biopharma companies. Throughout her career, Zara has leveraged human-centered innovation to empower people and to realize her commitment to improve healthcare access for patients with unmet needs.

"Digital innovation is so important so that we can help patients and healthcare professionals learn more, faster and more reliably. The addition of Zara to the VUE team is moving us light years ahead of where we were," said Kathryn Wilson, CEO. "Zara is such an innovative thinker and problem solver and a real team player. She seamlessly has integrated into the agency and always surprises us with her unique ideas."

"In the era of hyper-innovation agile companies have a competitive edge and I am excited to be a part of an adaptive agency that is committed to empowering healthcare clients through impactful work aligned to our client's business goals," said Zara. "I admire VUE Health for its collaborative culture, leadership, impressive clients and for being one of the best woman-owned agencies in the New England area."

For more information, please contact
Susan Torres
[email protected]
617-440-8003
Social: FacebookLinkedIn
Learn more about us on our website.

About VUE Health: VUE Health is a Boston-based, full-service pharmaceutical advertising agency focused on innovation, advancement, and the fearless pursuit of bringing science, education, and medicine to those in need. VUE Health is also certified as a Women's Business Enterprise (WBE) by WBENC. This prestigious certification acknowledges our woman-owned and operated business, meeting WBENC's rigorous standards. We're proud to empower women in business and promote diversity. We skillfully navigate healthcare brands' challenges with strategies grounded in understanding and creatively innovate to drive success.

SOURCE VUE Health


These press releases may also interest you

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

at 02:05
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces the opening of its proposed $100 million tender offer (the "Tender...



News published on and distributed by: